Results 51 to 60 of about 44,151 (306)

Carvedilol

New England Journal of Medicine, 1999
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. Follow up was limited to 16 weeks. A placebo-controlled, double-blind trial involving 1094 patients showed beneficial effects on overall ...
  +7 more sources

PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY)

Рациональная фармакотерапия в кардиологии, 2016
Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based on carvedilol or metoprolol in patients with arterial hypertension (HT) 1-2 degrees and overweight/obesity. To assess effects of carvedilol therapy on 10-year expected
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov   +4 more
doaj   +1 more source

Development of Carvedilol-Loaded Albumin-Based Nanoparticles with Factorial Design to Optimize In Vitro and In Vivo Performance

Pharmaceutics, 2023
Carvedilol, an anti-hypertensive medication commonly prescribed by healthcare providers, falls under the BCS class II category due to its low-solubility and high-permeability characteristics, resulting in limited dissolution and low absorption when taken
Mohamed S. Attia, Mohamed F. Radwan, Tarek S. Ibrahim, Tarek M. Ibrahim   +3 more
doaj   +1 more source

Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers [PDF]

Pharmacia, 2023
A Carvedilol is a member of BCS class II, it has a low solubility and bioavailability. This work intends to increase the solubility of carvedilol using a multicomponent crystal method.
Iyan Sopyan, Wuri Ariestika Sari, Sandra Megantara, Taofik Rusdiana   +3 more
doaj   +3 more sources

Case of chronic indolent pheochromocytoma that caused medically controlled hypertension but treatment-resistant diabetes mellitus [PDF]

, 2017
No abstract ...
Cho, Eun Joo, Dominiczak, Anna F., Jennings, Garry L.R., Lee, Hae-Young, Lee, HyunJung   +4 more
core   +1 more source

Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention

Pharmaceutics, 2020
The β-blocker carvedilol has been shown to prevent skin carcinogenesis in vitro and in vivo. Since systemic absorption of the β-blocker may cause cardiovascular disturbance, we developed a carvedilol loaded transfersome for skin-targeted delivery ...
Mengbing Chen, M. Shamim, A. Shahid, S. Yeung, B. Andresen, Jeffrey R. Wang, V. Nekkanti, F. Meyskens, K. Kelly, Ying Huang   +9 more
semanticscholar   +1 more source

Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

Trials, 2018
Background Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (
Dong-Ju Choi, Chan Soon Park, Jin Joo Park, Hae-Young Lee, Seok-Min Kang, Byung-Su Yoo, Eun-Seok Jeon, Seok Keun Hong, Joon-Han Shin, Myung-A Kim, Dae-Gyun Park, Eung-Ju Kim, Soon-Jun Hong, Seok Yeon Kim, Jae-Joong Kim   +14 more
doaj   +1 more source

Enantioselective Resolution of (R,S)-Carvedilol to (S)-(−)-Carvedilol by Biocatalysts

Natural Products and Bioprospecting, 2017
Among the microorganisms employed in the study, Aspergillus niger (GUFCC5443), Escherichia coli (ATCC9637), Streptomyces halstedii (CKM-2), Pseudomonas putida (NCIB9494), Cunninghamella elegans (NCIM689) and Sphingomonas paucimobilis (NCTC11030) were capable for the enantioselective conversion of racemic Carvedilol.
Swetha Ettireddy, Vijitha Chandupatla, Ciddi Veeresham   +2 more
openaire   +3 more sources

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial [PDF]

, 2000
BACKGROUND: In addition to its known properties as a competitive, nonselective beta and alpha-1 receptor blocker, carvedilol directly inhibits vascular myocyte migration and proliferation and exerts antioxidant effects that are ...
Betriu, A., Bonnier, J.J.R.M. (Hans), Coste, P. (Pierre), Foley, D.P. (David), Glogar, H.D. (Helmut), Goicolea, J. (Javier), Hauf-Zachariou, U., Hofling, B., Katus, H.A. (Hugo), Melkert, R. (Rein), Montauban van Swijndregt, E.W.J. (Eline), Puel, J. (Jacques), Rutsch, W.R. (Wolfgang), Seabra-Gomes, R. (Ricardo), Serruys, P.W.J.C. (Patrick), Simon, R. (Rudiger), Wijns, W. (William)   +16 more
core   +1 more source